title: The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression.
abstract: Expression of CD44 splice isoforms has been previously reported to correlate with inferior outcomes in DLBCL patients treated with CHOP therapy. However, it is unclear whether this observation remains valid in the R-CHOP era. In this study, we correlated CD44H and CD44v6 status with survival outcomes among DLBCL patients with an emphasis on the comparison between CHOP- and R-CHOP-treated subgroups. Our results suggest that rituximab has significantly decreased the prognostic value of CD44H. We also observed that the therapeutic benefit of rituximab is largely restricted to CD44H-positive cases in this cohort.
authors.forename: Xiaolei
authors.initials: X
authors.lastname: Wei
authors.forename: Meng
authors.initials: M
authors.lastname: Xu
authors.forename: Yongqiang
authors.initials: Y
authors.lastname: Wei
authors.forename: Fen
authors.initials: F
authors.lastname: Huang
authors.forename: Tong
authors.initials: T
authors.lastname: Zhao
authors.forename: Xiangzhao
authors.initials: X
authors.lastname: Li
authors.affiliation: Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China. ruth1626@hotmail.com.
authors.forename: Ru
authors.initials: R
authors.lastname: Feng
authors.forename: B Hilda
authors.initials: BH
authors.lastname: Ye
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D018960:Hyaluronan Receptors / Q000096:biosynthesis*; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D020033:Protein Isoforms / Q000096:biosynthesis; D012189:Retrospective Studies; D000069283:Rituximab; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C497483:CD44 protein, human; D018960:Hyaluronan Receptors; D020033:Protein Isoforms; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
references.citation: Mod Pathol. 1999 May;12(5):546-52
references.pmid: 10349995
references.citation: Oncogene. 2014 Jan 30;33(5):537-8
references.pmid: 23831568
references.citation: Leukemia. 1990 Aug;4(8):595-9
references.pmid: 1974938
references.citation: J Clin Oncol. 2006 Jul 1;24(19):3121-7
references.pmid: 16754935
references.citation: J Hematol Oncol. 2012 Oct 11;5:64
references.pmid: 23057966
references.citation: N Engl J Med. 2002 Jan 24;346(4):235-42
references.pmid: 11807147
references.citation: Lancet Oncol. 2006 May;7(5):379-91
references.pmid: 16648042
references.citation: Nat Rev Mol Cell Biol. 2003 Jan;4(1):33-45
references.pmid: 12511867
references.citation: Leukemia. 1999 Sep;13(9):1448-55
references.pmid: 10482998
references.citation: Hematology Am Soc Hematol Educ Program. 2012;2012:402-9
references.pmid: 23233611
references.citation: Lancet Oncol. 2008 Feb;9(2):105-16
references.pmid: 18226581